NCT03534986

Brief Summary

The impact of high-frequency chest wall oscillation therapy on spirometry values (Forced Expiratory Volume, Forced Vital Capacity, Peak Expiratory Flow, Forced Expiratory Flow and Tidal Volume is investigated during use of several products and comparing to baseline values.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 20, 2018

Completed
24 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 16, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 16, 2018

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 14, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 23, 2018

Completed
4 months until next milestone

Results Posted

Study results publicly available

September 6, 2018

Completed
Last Updated

October 3, 2018

Status Verified

September 1, 2018

Enrollment Period

24 days

First QC Date

May 14, 2018

Results QC Date

August 9, 2018

Last Update Submit

September 5, 2018

Conditions

Outcome Measures

Primary Outcomes (5)

  • TV

    Tidal Volume, the lung volume representing the normal volume of air displaced between normal inhalation and exhalation when extra effort is not applied

    30 minutes

  • PEF

    Peak Expiratory Flow, a person's maximum speed of expiration

    30 minutes

  • FVC

    Forced Vital Capacity, the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible

    30 minutes

  • FEV1

    Forced Expiratory Volume, the volume of air that can be forced out in one second after taking a deep breath

    30 minutes

  • FEF25-75%

    Forced Expiratory Flow (25-75%), the peak expiratory flow at 25 - 75% FVC

    30 minutes

Study Arms (3)

AffloVest The Vest Arm

EXPERIMENTAL

Devices placed on highest intensity / highest frequency

Device: International Biophysics AffloVestDevice: Hill-Rom The Vest

AffloVest inCourage Arm

EXPERIMENTAL

Devices placed on highest intensity / highest frequency

Device: International Biophysics AffloVestDevice: Respirtech inCourage

AffloVest SmartVest Arm

EXPERIMENTAL

Devices placed on highest intensity / highest frequency

Device: International Biophysics AffloVestDevice: Electromed SmartVest

Interventions

High-frequency chest wall oscillation vest

AffloVest SmartVest ArmAffloVest The Vest ArmAffloVest inCourage Arm

High-frequency chest wall oscillation vest

AffloVest The Vest Arm

High-frequency chest wall oscillation vest

AffloVest inCourage Arm

High-frequency chest wall oscillation vest

AffloVest SmartVest Arm

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy subject, ages 18 - 50

You may not qualify if:

  • Non-ambulatory, diagnosed neuromuscular disorder, currently using any type of oscillation vest therapy, diagnosed co-morbid condition (i.e. lung cancer, other lung disorder or disease), currently enrolled in a medical research study, non-English speaking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

PDS Research

Kissimmee, Florida, 34741, United States

Location

MeSH Terms

Conditions

Cystic FibrosisBronchiectasis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, DiseasesBronchial Diseases

Results Point of Contact

Title
VP of Engineering and Quality
Organization
International Biophysics Corporation

Study Officials

  • Thomas W O'Brien, MD

    PDS Research

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2018

First Posted

May 23, 2018

Study Start

February 20, 2018

Primary Completion

March 16, 2018

Study Completion

March 16, 2018

Last Updated

October 3, 2018

Results First Posted

September 6, 2018

Record last verified: 2018-09

Data Sharing

IPD Sharing
Will not share

Locations